Showing 2561-2570 of 2894 results for "".
- Revance: ePosters Showcase Data for DaxibotulinumtoxinA and RHA Line at Maui Dermhttps://modernaesthetics.com/news/revance-eposters-showcase-data-for-daxibotulinumtoxina-and-rha-line-at-maui-derm/2473053/Three ePosters presented at the Maui Derm for Dermatologists 2021 meeting feature data for DaxibotulinumtoxinA for Injection and the RHA® Collection of hyaluronic acid based dermal fillers, both from Revance Therapeutics. Revance repo
- Fat Loss Accelerates Facial Aging, Not Gravityhttps://modernaesthetics.com/news/fat-loss-accelerates-facial-aging-not-gravity/2473051/The real culprit behind facial aging may be the loss of fat both near the surface of the skin and in deeper areas, not gravity or sagging, finds a
- Four Years Running: Alastin Leads in Growthhttps://modernaesthetics.com/news/four-years-running-alastin-leads-in-growth/2473044/Alastin Skincare®, Inc. is the Fastest Growing Brand in the US Professional Skincare Market for the fourth year in a row. That’s according to the latest rankings from consulting and research firm Kline Group's 2020 Professional Skincare: US Market Analysis and Opportunitie
- RealSelf Adds One Million Arabic-speaking Monthly Users With Tajmeeli.com Acquisitionhttps://modernaesthetics.com/news/realself-adds-1-million-arabic-speaking-monthly-users-with-tajmeelicom-acquisition/2473043/RealSelf now owns Tajmeeli, the leading cosmetic procedure resource for Arabic speaking consumers. The acquisition adds one million Arabic-speaking monthly active users. "We're excited this acquisition will enable us to expand our reach and resources to over 100 countries
- Soliton Taps Sean J. Shapiro as Vice President of Saleshttps://modernaesthetics.com/news/soliton-taps-sean-j-shapiro-as-vice-president-of-sales/2473037/Sean J. Shapiro is Soliton, Inc’s New Vice President of Sales, effective January 1, 2021. "We are very excited to have Sean join our team during this pivotal time for the company as we anticipate clearance of our 510(k) application for cellulite reduction duri
- Revance Therapeutics and Ajinomoto Bio-Pharma Services Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://modernaesthetics.com/news/revance-therapeutics-and-ajinomoto-bio-pharma-services-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2473035/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
- Done Deal: DermOQ Oxygen Lab Acquires ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://modernaesthetics.com/news/done-deal-dermoq-oxygen-lab-acquires-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2473034/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- Phase 2 DaxibotulinumtoxinA Data Highlight Efficacy for Upper Facial Lineshttps://modernaesthetics.com/news/phase-2-daxibotulinumtoxina-data-highlight-efficacy-for-upper-facial-lines/2473032/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- 2020 in Reviewhttps://modernaesthetics.com/news/2020-in-review-1/2473031/• The AmSpa Aesthetic Safety Council (AASC), designed to help the American Med Spa Association (AmSpa) further its goal of promoting compliance, safety, and profitability throughout the medical aesthetic industry, has launched. Even in the midst of the international COVI
- Revance Names Nashville Its New Homehttps://modernaesthetics.com/news/revance-names-nashville-its-new-home/2473029/Revance Therapeutics is relocating to Nashville. In conjunction with Tennessee Gov. Bill Lee and Tennessee Department of Economic and Community Development (TNECD) Commissioner Bob Rolfe, the company says it is leaving its current home in Silicon Valley’